Immunicon Overview

  • Founded
  • 1984

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 96

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $31M

Immunicon General Information

Description

Developer and manufacturer of cell-based diagnostic and research products. The company manufactures ultra-high sensitive cancer detection test kits (cancer blood test) and next generation cell analysis instruments (cell track cytometer) for various research and clinical applications.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Discovery Tools (Healthcare)
Acquirer
Veridex
Primary Office
  • 3401 Masons Mill Road
  • Suite 100
  • Huntingdon Valley, PA 19006
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunicon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-Aug-2008 $31M 0000 Completed Generating Revenue/Not Profitable
6. Bankruptcy: Admin/Reorg 11-Jun-2008 Completed Bankruptcy: Admin/Reorg
5. IPO 16-Apr-2004 000.00 Completed Generating Revenue
4. Later Stage VC (Series F) 01-Jul-2003 000.00 000.00 Completed Generating Revenue
3. Later Stage VC 01-Jan-2002 000.00 000.00 Completed Generating Revenue
2. Later Stage VC 11-Sep-2000 $21.8M $31.8M Completed Generating Revenue
1. Later Stage VC (Series D) 01-Jan-1999 $10M $10M Completed Generating Revenue
To view Immunicon’s complete valuation and funding history, request access »

Immunicon Patents

Immunicon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20070212698-A1 Operator independent programmable sample preparation and analysis system Granted 13-Mar-2006 0000000000 00
US-8337755-B2 Operator independent programmable sample preparation and analysis system Active 13-Mar-2006 0000000000 0
US-9127302-B2 System for the detection and enumeration of suspect target cells in a mixed cell population Active 24-Oct-2005 00000000
EP-3211086-A2 Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes Granted 20-Sep-2005 0000000000
EP-3211086-B1 Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes Active 20-Sep-2005 C12Q1/6886
To view Immunicon’s complete patent history, request access »

Immunicon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunicon Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Anthem Capital Management Venture Capital Minority 000 0000 000000 0
Burrill & Co Merchant Banking Firm Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Claneil Enterprises Holding Company Minority 000 0000 000000 0
Equity4Life Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »